Resolutions Passed at Sartorius Stedim Biotech's Annual Shareholders’ Meeting

On March 26, 2024, Sartorius Stedim Biotech S.A. held its Annual Shareholders’ Meeting in Aubagne, France, where several significant resolutions were passed with broad support from the shareholders. The company announced the extensive approval of all directors, including the renewal of Susan Dexter and Anne-Marie Graffin as Directors for an additional three-year term.

The Board of Directors will continue with its current composition including Joachim Kreuzburg as Chairman and René Fáber as CEO, alongside other important figures, reinforcing its continuity and stability. Additionally, in a move that rewards shareholders, a dividend of 0.69 euros per share for the fiscal year 2023 was approved, totaling a distribution of 67.1 million euros. This dividend is set to be paid out on April 4, 2024.

Sartorius Stedim Biotech also highlighted its forward-looking plans and potential risks, emphasizing the forward-looking nature of certain statements within the press release. The company's strong global presence and its role as an essential partner in the biopharmaceutical industry were reaffirmed, with a focus on innovative solutions for manufacturing biotech medications. The financial calendar extending to October 2024 was outlined, marking key dates for the publication of financial figures.